Retinopathy, Diabetic Clinical Trial
Official title:
DEXTENZA VS. PREDNISOLONE ACETATE 1% in the Incidence of Pseudophakic Macular Edema in Patients With Diabetic Retinopathy Undergoing Cataract Surgery
The complicated schedules for administering topical steroid eye drops combined with forgetfulness and physical difficulties instilling the drops may compromise compliance; which in turn could increase the risk for secondary complications such as PME post-cataract surgery, especially in a high-risk diabetic population. Dextenza, a sustained- release steroid insert, could help preclude adherence difficulties and provide better bioavailability, being as effective as, or more effective than steroid drops in preventing PME. The aim of this study is to assess the incidence of PME in diabetic patients undergoing cataract surgery when comparing the Dextenza insert to topical prednisolone acetate 1% drops.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | March 2022 |
Est. primary completion date | February 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Binocular - >18 years old - Any level of Background Diabetic Retinopathy - Cataract surgery candidate in each eye - Pre-operative OCT and Fluorescein Angiography showing no Macular edema Exclusion Criteria: - Participant cannot complete second eye operation within 60 days of the first cataract surgery - Maintains regular use of systemic or ocular steroids at time of enrollment - Maintains regular use of systemic or ocular non-steroidal anti-inflammatory drugs at time of enrollment - Anterior chamber cells present at time of enrollment - Recent febrile illness that precludes or delays participation for 90 days - Pregnancy or lactation - Known allergy to dexamethasone - Known allergy to prednisolone - Preexisting retinal disease including uveitis, nondiabetic retinal disease, choroidal disorders, diabetic macular edema. - Posterior capsule rupture or other intraoperative complication in first eye operated on - Amblyopia - Anti-VEGF injections within 6 months prior to surgery day. - Intraocular steroid injection within 6 months prior to surgery day. - Intraocular surgeries within 6 months prior to surgery day. - Laser photocoagulation within 30 days prior to surgery day. - Any type of eye inflammation - Any punctum inflammation or dacryocystitis |
Country | Name | City | State |
---|---|---|---|
United States | Ophthalmic Consultants of the Capital Region | Troy | New York |
Lead Sponsor | Collaborator |
---|---|
Ophthalmic Consultants of the Capital Region |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To measure the effect of 0.4mg dexamethasone intracanalicular insert in preventing PME in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1% as measure. | Percentage of eyes that developed post-surgical PME in each group measured on fluorescein angiography at Day 7 on Optical Coherence Tomography at Day 7 by a masked grader. | 7 days | |
Primary | To measure the effect of 0.4mg dexamethasone intracanalicular insert in preventing PME in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1% as measure. | Percentage of eyes that developed post-surgical PME in each group measured on optical coherence tomography at Day 30 by a masked grader. | 30 days | |
Primary | To measure the effect of 0.4mg dexamethasone intracanalicular insert in preventing PME in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1% as measure. | Percentage of eyes that developed post-surgical PME in each group measured on fluorescein angiography at Day 60 and on optical coherence tomography at Day 60 by a masked grader. | 60 days | |
Secondary | Incidence of central subfield thickness (CST) at Day 7 post op as seen on optical coherence tomography (OCT) | Mean central subfield thickness (CST) at Day 7 post op in each group and comparison between groups. | 7days | |
Secondary | Incidence of central subfield thickness (CST) at Day 7 post op as seen on optical coherence tomography (OCT) | Mean central subfield thickness (CST) at Day 30 post op in each group and comparison between groups. | 30 days | |
Secondary | Incidence of central subfield thickness (CST) at Day 60 post op as seen on optical coherence tomography (OCT) | Mean central subfield thickness (CST) at Day 60 post op in each group and comparison between groups. | 60 days | |
Secondary | To measure the change in CST inflammation outcomes and in diabetic patients as seen on optical coherence tomography (OCT), Dextenza compared to topical prednisolone acetate 1%. | Mean change in CST from Baseline at Day 7, Day 30 and Day 60 and comparison between groups. | 7 days | |
Secondary | To measure the change in CST inflammation outcomes and in diabetic patients as seen on optical coherence tomography (OCT), Dextenza compared to topical prednisolone acetate 1%. | Mean change in CST from Baseline at Day 7, Day 30 and Day 60 and comparison between groups. | 30 days | |
Secondary | To measure the change in CST inflammation outcomes and in diabetic patients as seen on optical coherence tomography (OCT), Dextenza compared to topical prednisolone acetate 1%. | Mean change in CST from Baseline at Day 7, Day 30 and Day 60 and comparison between groups. | 60 days | |
Secondary | To measure the effect of 0.4mg dexamethasone intracanalicular insert in vision in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1%. | Difference of mean ETDRS Best Corrected Visual Acuity (BCVA) between groups at Day 7 post op | 7 days | |
Secondary | To measure the effect of 0.4mg dexamethasone intracanalicular insert in vision in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1%. | Difference of mean ETDRS Best Corrected Visual Acuity (BCVA) between groups at Day 30 post op | 30 days | |
Secondary | To measure the effect of 0.4mg dexamethasone intracanalicular insert in vision in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1%. | Difference of mean ETDRS Best Corrected Visual Acuity (BCVA) between groups at Day 60 post op | 60 days | |
Secondary | Difference patients with absence of anterior chamber (AC) cells at Day 7 post op | Percentage of patients who had absence of Anterior Chamber (AC) cells at Day 7 | 7 days | |
Secondary | Difference patients with absence of anterior chamber (AC) cells at Day 30 post op | Percentage of patients who had absence of Anterior Chamber (AC) cells at Day 30 | 30 days | |
Secondary | Difference patients with absence of anterior chamber (AC) cells at Day 60 post op | Percentage of patients who had absence of Anterior Chamber (AC) cells at Day 60 | 30 days | |
Secondary | Self reported patient experience of comfort | Self-reported patient experience of comfort (right eye vs. left eye) at Day 60. | 60 days | |
Secondary | Rescue Therapy | Percentage of eyes rescued in each group. | 60 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06066021 -
Evaluation of a Health Education Program for Type 2 Diabetes Patients
|
N/A | |
Recruiting |
NCT06376240 -
The Effect of Pyridoxamine Supplementation on Microvascular Function in Type 2 Diabetes
|
N/A | |
Completed |
NCT01506895 -
A Phase 2 Clinical Study to Investigate Effects of Darapladib in Subjects With Diabetic Macular Edema
|
Phase 2 | |
Recruiting |
NCT04025996 -
REWARD: Using the REtina as a Window To Detect Cardiac microvasculAR Dysfunction In Diabetes Mellitus
|
||
Withdrawn |
NCT04702048 -
Evaluation of the Retina in Patients With Non-proliferative Diabetic Retinopathy After Aflibercept Injection in the Eye
|
Phase 4 | |
Completed |
NCT03345667 -
Assessment of Color Vision in Diabetic Patients
|
N/A | |
Recruiting |
NCT05746975 -
Diabetic Retinopathy Classification: ETDRS 7-fields vs Widefield Imaging (ClarusDR)
|